Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections

摘要

The disadvantages of standard HIV therapies are as follows: currently used medicaments must be taken in large quantities each day during an entire lifetime according to a strict timetable and have a large number of side effects. Traditional medicaments only manage to restrict virus replication. Host cells infected with HIV are not eliminated. For this reason it was not previously possible to cure HIV infections. The current application describes, as an additional application to PCT patent application (PCT/DE99/00598) dated 8.3.99, radio-immunological pharmaceuticals consisting of a CD4 molecule or a fragment derived therefrom and a radionuclide for in-vivo elimination of HIV replicating cells in HIV-1 and HIV-2 infected patients. The combination of HIV affine CD4 receptor molecules or fragments with radionuclides for therapeutic purposes, especially for use in radioimmunological anti-HIV therapy is totally novel. The radioimmunological pharmaceuticals are to be administered intravenously to HIV-1 or HIV-2 infected patients once or in several cycles in order to cause sustained damage to HIV replicating cells in a targeted manner so that the latter can be fully eliminated.